Myqorzo Launch Beats Expectations, But Structural Risks Remain

What happened

Cytokinetics announced that the commercial launch of Myqorzo (aficamten) for obstructive HCM is tracking ahead of internal expectations, with positive physician feedback on the label, REMS program, and recent clinical data. While this early signal is encouraging, it must be weighed against the DeepValue report's assessment that the stock is a potential sell, given Camzyos' entrenched position (12,500+ patients), a leveraged balance sheet (negative equity of $521M), and dependence on flawless execution. The favorable launch commentary provides a near-term validation but does not yet address the structural challenges of capturing significant share from an incumbent with $602M in 2024 sales and a simplified label. Investor focus should remain on hard metrics like script volumes and payer adoption over the next two quarters to gauge whether this momentum is sustainable.

Implication

If Myqorzo continues to exceed expectations and demonstrates clear share gains vs Camzyos over the next 6–12 months, the thesis could shift. However, investors should wait for concrete evidence of sustained traction (e.g., quarterly sales exceeding $100M run-rate) and ACACIA nHCM data before committing significant capital. The current valuation already discounts a high degree of success.

Thesis delta

The early launch beat adds a positive data point that modestly increases the probability of the bull case (25% to 30%) but does not yet change the fundamental risk:reward skew. The core thesis remains that Cytokinetics is overvalued given Camzyos' momentum, the REMS line-item parity, and the leveraged capital structure. Confirmation of sustained above-consensus sales or strong ACACIA data would be needed to reconsider the sell rating.